STOCK TITAN

Edwards Lifesciences (EW) SVP awarded RSUs, options and has shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported routine equity compensation changes. On May 7, 2026, he acquired 7,005 shares of Common Stock through grants at no cost and received employee stock options on 6,745 shares with an exercise price of $82.76 per share.

The restricted stock units and options were granted under the company’s Long-Term Stock Incentive Compensation Program and are scheduled to vest and become exercisable in four equal annual installments starting one year after the grant date. On May 8, 2026, 289 shares of Common Stock were withheld at $82.76 per share to cover tax obligations, leaving Dahl with 15,901.6214 shares of Common Stock held directly after these transactions.

Positive

  • None.

Negative

  • None.
Insider Dahl Andrew M.
Role SVP, Corporate Controller
Type Security Shares Price Value
Tax Withholding Common Stock 289 $82.76 $24K
Grant/Award Employee Stock Option (Right to Acquire) 6,745 $0.00 --
Grant/Award Common Stock 3,985 $0.00 --
Grant/Award Common Stock 3,020 $0.00 --
Holdings After Transaction: Common Stock — 15,901.621 shares (Direct, null); Employee Stock Option (Right to Acquire) — 6,745 shares (Direct, null)
Footnotes (1)
  1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
RSU grants 7,005 shares Restricted stock units granted on May 7, 2026
Stock options granted 6,745 options Employee stock options granted May 7, 2026
Option exercise price $82.76 per share Exercise price for 6,745 stock options
Tax-withholding shares 289 shares Shares withheld for tax obligations on May 8, 2026
Price for tax withholding $82.76 per share Value used for 289-share tax-withholding disposition
Post-transaction holdings 15,901.6214 shares Common Stock directly held after transactions
Derivative transactions 1 transaction Single derivative grant reported in Form 4
Tax-withholding count 1 transaction One F-code tax-withholding disposition
restricted stock units financial
"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Option (Right to Acquire) financial
"security_title": "Employee Stock Option (Right to Acquire)""
Long-Term Stock Incentive Compensation Program financial
"under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested"
tax-withholding disposition financial
"transaction_action": "tax-withholding disposition""
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
grant/award acquisition financial
"transaction_action": "grant/award acquisition""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dahl Andrew M.

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, Corporate Controller
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A3,985(1)A$0.000013,170.6214D
Common Stock05/07/2026A3,020(1)A$0.000016,190.6214D
Common Stock05/08/2026F289D$82.7615,901.6214D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Acquire)$82.7605/07/2026A6,74505/07/2027(2)05/06/2033Common Stock6,745$0.00006,745D
Explanation of Responses:
1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
2. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.
Linda J. Park, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Edwards Lifesciences (EW) report for Andrew M. Dahl?

Edwards Lifesciences reported that Andrew M. Dahl received equity awards and a small tax-related share withholding. He was granted restricted stock units, stock options, and had 289 shares withheld to satisfy tax liabilities, all as part of routine compensation arrangements.

How many Edwards Lifesciences (EW) shares did Andrew M. Dahl acquire in this Form 4?

Andrew M. Dahl acquired 7,005 shares of Edwards Lifesciences Common Stock through restricted stock unit grants. These shares were granted at no purchase price as part of his long-term incentive compensation, reflecting equity-based pay rather than open-market stock purchases.

What stock options did Andrew M. Dahl receive from Edwards Lifesciences (EW)?

Andrew M. Dahl received employee stock options covering 6,745 shares of Edwards Lifesciences Common Stock. The options have an exercise price of $82.76 per share and vest in four equal annual installments beginning one year after the May 7, 2026 grant date.

Why were 289 Edwards Lifesciences (EW) shares disposed of in this filing?

The 289 Edwards Lifesciences shares were withheld to pay tax liabilities related to equity compensation. This tax-withholding disposition is coded as an F transaction and does not represent an open-market sale, but rather automatic shares used to cover required taxes.

How many Edwards Lifesciences (EW) shares does Andrew M. Dahl hold after these transactions?

After the reported transactions, Andrew M. Dahl directly holds 15,901.6214 shares of Edwards Lifesciences Common Stock. This post-transaction balance reflects the new grants he received, net of the 289 shares withheld to satisfy associated tax obligations.

When do Andrew M. Dahl’s new Edwards Lifesciences (EW) equity awards vest?

Both the restricted stock units and stock options granted on May 7, 2026 are scheduled to vest and become exercisable in four equal annual installments. Vesting begins one year after the grant date, providing a multi-year incentive alignment with company performance.